ArticleDiscover oncology2025
The role of mitochondria-related genes in hepatocellular carcinoma prognosis: construction of prognostic models based on machine learning.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and validation of a machine learning-driven mitochondrial gene signature for the diagnosis of breast cancer.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC), a common and lethal form of liver cancer, includes mitochondrial dysfunction in its pathogenesis.
objectivesThis study investigated the relationship between mitochondrial function-related genes and HCC progression.
methodsWe systematically retrieved mitochondrial genetic data from the MitoCarta database and identified differentially expressed genes through Gene Expression Omnibus analysis. Weighted gene co-expression network analysis was subsequently employed to construct co-expression networks and identify key modules associated with HCC progression. We evaluated 113 machine learning algorithms to develop mitochondrial gene-based prognostic models. Gene set enrichment analysis further delineated the pathways and biological processes enriched in the module hub genes, offering mechanistic insights into HCC. Immune infiltration analysis using CIBERSORT highlighted the pivotal roles of M1 and M2 macrophages in HCC. Finally, therapeutic candidates targeting critical genes were explored using computational drug prediction, molecular docking, and molecular dynamic simulations, providing novel strategies for HCC-targeted therapy.
resultsStepwise Logistic Regression with Gradient Boosting Machine was chosen as the optimal model (area under the curve [AUC] = 0.977). Moreover, 15 potential HCC biomarkers were identified, including PSMD4 (AUC = 0.888), TBCE (AUC = 0.879), and CKS1B (AUC = 0.860). Additionally, fluoxetine and paroxetine were predicted as potential HCC drugs and validated through molecular docking and dynamic simulations.
conclusionsThis study highlights the prognostic significance of mitochondrial function-related genes in HCC and establishes a framework for developing innovative diagnostic and therapeutic interventions. Future research should prioritize clinical validation of these findings and evaluate the translational potential of the identified drug candidates in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.